News Releases

Date Title and Summary View
Apr 26, 2018
Johnson & Johnson Announces Dividend Increase of 7.1%
Johnson & Johnson Announces Dividend Increase of 7.1% NEW BRUNSWICK, N.J., April 26, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 7.1% increase in the quarterly dividend rate, from $0.84 per share to $0.90 per share.  The increase was
Apr 24, 2018
Johnson & Johnson to Participate in the 2018 Deutsche Bank 43rd Annual Health Care Conference
NEW BRUNSWICK, N.J. , April 24, 2018 /PRNewswire/ --  Johnson & Johnson (NYSE: JNJ) will participate in the 2018 Deutsche Bank 43 rd Annual Health Care Conference on Wednesday, May 9 th , at The InterContinental Boston .  Mathai Mammen, MD, Ph.D., Global Head, Research & Development, Janssen
Apr 17, 2018
Johnson & Johnson Reports 2018 First-Quarter Results:
2018 First-Quarter Sales of $20.0 Billion Increased 12.6% versus 2017
2018 First-Quarter EPS was $1.60
2018 Adjusted First-Quarter EPS of $2.06 increased 12.6%*
Sales Momentum Continued in the First Quarter
Strong Adjusted EPS Growth of 12.6%*
Company Increased Sales and Reaffirms EPS Guidance
Apr 16, 2018
Apr 12, 2018
INVOKANA® (canagliflozin) Demonstrated Significant Renal Protective Benefits in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
New analysis further supports the potential renal protective effects of INVOKANA ® Austin, TX, April 12, 2018 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced an additional analysis from the landmark CANVAS Program showing INVOKANA ® (canagliflozin) improved renal
Apr 11, 2018
Johnson & Johnson Vision Announces Revolutionary Contact Lens Innovation with ACUVUE OASYS® with Transitions® Light Intelligent Technology™
Developed in strategic partnership with Transitions Optical, this one-of-a-kind contact lens corrects vision and adapts to changing light conditions
Mar 20, 2018
Dominic J. Caruso to Retire as Chief Financial Officer of Johnson & Johnson
Joseph Wolk Promoted to Executive Vice President, Chief Financial Officer
Mar 20, 2018
Mar 16, 2018
Johnson & Johnson Announces Binding Offer from Platinum Equity to Acquire LifeScan, Inc.
NEW BRUNSWICK, N.J. , March 16, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that it has received a binding offer from Platinum Equity, a leading private investment firm, to acquire its LifeScan business for approximately $2.1 billion , subject to customary adjustments.
Mar 15, 2018
This site uses cookies as described in our Cookie Policy Please click the "Accept" button or continue to use our site if you agree to our use of cookies.